Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Kim, Seok Jin  [Clear All Filters]
2013
Ohmachi K, Niitsu N, Uchida T, Kim SJin, Ando K, Takahashi N, Takahashi N, Uike N, Eom HSeok, Chae YSoo, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2013.
Kim SJin, Yoon DHyun, Yang D-H, Eom HSeok, Cho SGoo, Yoon S-S, Lee JHoon, Kim WSeog, Suh C. Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Res. 2013;48(2):72-3.
2014
Ahn S-Y, Jung S-H, Joo YDon, Lee WSik, Lee SMin, Choi CWon, Kim SJin, Kim K, Lee J-J. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol. 2014.
2016
Park S, Kim K, Jang JHo, Kim SJin, Kim WSeog, Jung CWon. Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016.
Park S, Kim K, Jang JHo, Kim SJin, Kim WSeog, Chung DRyeon, Kang C-I, Peck KRan, Jung CWon. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infect. 2016.
2018
Jeong SHyun, Song H-N, Park JSeong, Yang D-H, Koh Y, Yoon S-S, Lee HWon, Eom HSeok, Won J-H, Kim WSeog, et al. Allogeneic stem cell transplantation for patients with natural killer/T-cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transplant. 2018.
2020
Kim KHa, Kim WSeog, Kim SJin, Yoon DHyun, Suh C, Kang HJin, Choi CWon, Lee HSup, Bae SHwa, Park J, et al. Treatment with Intravenous Busulfan, Melphalan, and Etoposide (BuME) followed by Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from the Consortium for Improving Survival of Lymphoma (CISL). Transpl Int. 2020.
2022
Yoon SEun, Kim D, Choi J-O, Min J-H, Kim BJoon, Kim J-S, Lee JEun, Choi JYoung, Jeon E-S, Kim SJin, et al. A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea. Int J Hematol. 2022.
Yi JHo, Jeong SHyun, Kim SJin, Yoon DHyun, Kang HJin, Koh Y, Kim JSeok, Lee W-S, Yang D-H, Do YRok, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Res Treat. 2022.
Kim HRyeon, Yoon SEun, Kim D, Choi J-O, Min J-H, Kim BJun, Kim JSun, Lee JEun, Choi JYoung, Jeon E-S, et al. Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea. Clin Lymphoma Myeloma Leuk. 2022.
2023
Kim SJin, Jo J-C, Yoon DHyun, Yang D-H, Yoon SEun, Lee G-W, Kong JHyun, Park Y, Kang K-W, Lee H-S, et al. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. Front Oncol. 2023;13:1230629.
Cho H, Yoon DHyun, Shin D-Y, Koh Y, Yoon S-S, Kim SJin, Do YRok, Lee G-W, Kwak J-Y, Park Y, et al. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404). Cancer Res Treat. 2023.
Jeon Y, Yoon SEun, Cho J, Kim SJin, Kim WSeog. Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma. Ann Hematol. 2023.